With the many regulations and the increased attention on antipsychotic use in skilled nurse facilities, there is much to review and consider in 2020. Consultant Pharmacists and advanced practice nurses work together to address the use of psychoactive medications in skilled nursing facilities and having a common educational webinar that discusses best practices and further discusses future directions of practice is critical to patients residing in this health care environment. This webinar will provide deep practical experience from national thought leaders on how to manage antipsychotic medications for patients in this increasingly regulated environment.
Continuing Education Instructions and Disclosure Information
Contact hours available until 4/30/22.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Disclosures:
Planning Committee: No planning committee discloses a potential or actual conflict of interest.
Speakers: No speaker discloses a potential or actual conflict of interest.
Commercial Support and Sponsorship:
This activity is supported by an education grant from Acadia Pharmaceuticals
Accreditation Statement:
This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) the Gerontological Advanced Practice Nurses Association (GAPNA) and American Society of Consultant Pharmacists (ASCP)
Anthony J. Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Anthony J. Jannetti, Inc. is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP5387.
Learning Outcome:
After completing this continuing nursing education activity, the learner will be able to work with other health care professionals to ensure that patients managed with antipsychotic medications are monitored for appropriateness, safety and efficacy.